201 Brookline Avenue
Suite 601
Cambridge, MA 02215
United States
617 603 0070
https://www.vervetx.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 255
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Dr. Sekar Kathiresan M.D. | Co-Founder, CEO & Director | 973.25k | N/D | 1973 |
Ms. Joan Nickerson M.B.A. | Chief Administrative Officer | N/D | N/D | 1969 |
Ms. Jennifer Robinson | Vice President of Investor Relations & Corporate Communications | N/D | N/D | N/D |
Ms. Kaitlin Duffy | Executive Director of Human Resources | N/D | N/D | N/D |
Mr. Yasser M. El-Gamal J.D. | Senior VP of Legal Affairs & Chief Intellectual Property Counsel | N/D | N/D | 1968 |
Mr. Jason Politi | Chief Technical Operations Officer | N/D | N/D | 1977 |
Dr. Troy Lister Ph.D. | Senior Vice President of Research & Early Development | N/D | N/D | N/D |
Dr. Leslie Stolz Ph.D. | Senior Vice President of Regulatory Affairs | N/D | N/D | N/D |
Ms. Jaime Kirk | Controller | N/D | N/D | N/D |
Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
La calificación ISS Governance QuickScore de Verve Therapeutics, Inc. a partir del 1 de mayo de 2024 es 8. Las puntuaciones principales son Auditoría: 8; Junta: 7; Derechos del accionista: 8; Compensación: 8.